1. What's New in Oral Combination Therapy for Type 2 Diabetes?

3. Introduction

4. Patient Characteristics of SGLT2 Inhibitor CVOTs

5. Published SGLT2 Inhibitor CVOT Study Cohorts

6. Patient Characteristics of SGLT2 Inhibitor CVOTs

7. Primary Endpoints of Published SGLT2 Inhibitor CVOTs

8. Role of SGLT2 Inhibitors in Improvement of Renal Outcomes

9. ADA 2019 Recommendations for Patients With Established ASCVD, HF, or CKD

10. Updates to ADA Standards of Medical Care in Diabetes

11. Baseline Characteristics of Published CVOT Trials for SGLT2 Inhibitors

12. Pooled Data for the Composite of MACE

13. Pooled Data for HHF by Presence of ASCVD

14. Effect of SGLT2 Inhibitor on Specific CV and Renal Outcomes

15. SGLT2 Inhibitors Provide Marked Benefits to Reduce HF and Progressive Renal Decline

16. Role of SGLT2 Inhibitors in Cardiorenal Complications of T2D

17. SGLT2 Inhibitor Combination Therapy

18. Appropriate Use of SGLT2 Inhibitor Combination Therapy

19. Barriers to Using Combination Therapy

20. Future Trials With SGLT2 Inhibitors

21. VERTIS-CV Trial CV and Renal Efficacy and Safety of Ertugliflozin

22. SGLT2 Inhibitors as Cardiovascular Drugs

23. Multispecialty Care of Patients With T2D

24. Concluding Remarks

25. Abbreviations

26. Abbreviations (cont)